NIH Clinical Research Studies

Protocol Number: 02-M-0021

Active Accrual, Protocols Recruiting New Patients

Title:
Severe Mood and Behavioral Dysregulation in Children: Pathophysiology and Treatment with Lithium
Number:
02-M-0021
Summary:
This study seeks to characterize symptoms of severe mood and behavioral dysregulation (SMBD) in children and adolescents. The study will also evaluate the effectiveness of lithium as a treatment for this condition while subjects participate in day-treatment or inpatient care.

Children with SMBD display chronic anger, sadness, irritability, hyperarousal symptoms (such as insomnia, distractibility) and extreme responses to frustration. Participants will be screened as outpatients using medical and psychiatric history and interview, physical examination, blood and urine tests, and an electrocardiogram.

Children with SMBD have current medications gradually withdrawn over 1- to 3-weeks and then are randomly assigned to receive either lithium or a placebo (sugar pill).

The treatment phase is 8 weeks and is provided on a children's inpatient unit or day treatment center, depending on clinical considerations. All children will receive placebos for at least 2 weeks during some part of the 8-week trial. During treatment, participants are rated on mood, behavior, and medication side effects. Blood tests are obtained weekly or as clinically indicated. At the end of the 8 week randomized trial, children who took placebo may be offered lithium. Children who took lithium but did not respond will be stabilized before returning to care in the community. Schooling is provided in the inpatient and day treatment programs.

Patients receive neuropsychological testing, experimental psychophysiological studies, magnetic resonance imaging (MRI) scans of brain structure, and research magnetic resonance spectroscopy (MRS) scans. . Patients are asked to wear activity monitors on their wrist. Information on family medical and psychiatric history is also obtained.

Patients are asked to return for follow-up visits once every 2 years for repeat interviews, medical, psychiatric and school histories, questionnaires, physical examination, blood work, and structural MRI. Participants will be followed over time and their symptoms will be compared with those of children with bipolar disorder (BPD) and healthy volunteers (controls).

Sponsoring Institute:
National Institute of Mental Health (NIMH)
Recruitment Detail
Type: Active Accrual Of New Subjects
Gender: Male & Female
Referral Letter Required: No
Population Exclusion(s): None

Eligibility Criteria:
INCLUSION CRITERIA (all 10 must be met):

1. Ages 7-17

2. Mood symptoms: periods of excessive anger, sadness, and/or irritability are present most days ("highly characteristic").

3. Hyperarousal, as defined by at least three of the following symptoms:

a. insomnia,

b. agitation,

c. distractibility,

d. racing thoughts or flight of ideas,

e. pressured speech,

f. intrusiveness

4. Marked Reactivity: The child frequently exhibits markedly increased reactivity to emotional stimuli that is manifest verbally or behaviorally. For example, the child responds to frustration with extended temper tantrums (inappropriate for age and/or precipitating event), verbal rages, and/or aggression toward people or property.

5. The symptoms in # 2, 3, and 4 above are currently present and have been present for at least 12 months without any symptom-free periods exceeding two months.

6. The mood symptoms and excessive reactivity are severe in at least in one setting (e.g. violent outbursts, assaultiveness at home, school, or with peers). In addition, there are at least mild symptoms (distractibility, intrusiveness) in a second setting.

7. If the child meets DSM-IV criteria for major depressive disorder, he/she must have had an adequate trial of an SSRI antidepressant (defined as four weeks of consecutive treatment in minimally effective doses among adults: paroxetine 20 mg; fluoxetine 20 mg; citalopram 20 mg; fluvoxamine 150 mg; sertraline 50 mg). His/her response to the treatment must have been no more than minimal (i.e. CGI-I greater than 2).

8. If the child meets DSM-IV criteria for attention deficit hyperactivity disorder, he/she must have had an adequate trial of methylphenidate (defined as two consecutive weeks of Ritalin, Metadate, Methylin, or Concerta, at least 30 mg/day if adverse effects present, and at least 60 mg/day if dose not limited by adverse effects), and an adequate trial of amphetamines two consecutive weeks of Adderall 20 mg/day or dextroamphetamine 40 mg/day). His/her response to the treatment must have been no more than minimal (i.e. CGI-I greater than 2).

9. Currently in treatment with a psychiatrist for the symptoms.

10. The child is failing his/her treatment. To meet this criterion:

a) The child's current CGAS score must be less than or equal to 60.

b) The child's psychiatrist must agree that the child's response to his/her current treatment is no more than minimal (i.e. CGI-I greater than 2). According to this criterion, it would be clinically appropriate to change the child's current treatment.

c) On the basis of record review and interviews with child and parent, the research team agrees that the child's response to his/her current treatment is no more than minimal (i.e. CGI-I greater than 2).

INCLUSION CRITERIA - CONTROLS:

Control subjects will be age- and sex- matched to the patients. They will have normal physical and neurological examinations and an identified primary care physician. Both control subjects and their first-degree relatives must be free of current or past psychopathology.

EXCLUSION CRITERIA:

1. The individual exhibits any of these cardinal bipolar symptoms:

Elevated or expansive mood;

Grandiosity or inflated self-esteem;

Decreased need for sleep;

Increase in goal-directed activity (this can result in excessive involvement in pleasurable activities that have a high potential for painful consequences)

2. The symptoms occur in distinct periods lasting more than 4 days , and therefore meet criteria for hypomania or mania.

3. Meets criteria for schizophrenia, schizophreniform disorder, schizoaffective illness, PDD, or PTSD.

4. Meets criteria for substance use disorder in the three months prior to randomization.

5. IQ less than 80

6. The symptoms are due to the direct physiological effects of a drug of abuse, or to a general medical or neurological condition.

7. The patient's symptoms have shown a marked response to current treatment.

8. Currently pregnant or lactating, or sexually active without using a barrier method of contraception.

9. Contraindications to treatment with lithium (e.g. renal, thyroid, cardiac disease, seizure disorder).

10. Previous adequate trial of treatment with lithium that did not have beneficial clinical effects. An adequate trial is defined as at least 6 weeks of treatment with a blood level of greater than or equal to 0.8 mEq/L.

EXCLUSION CRITERIA - CONTROLS:

I.Q. less than 80; ongoing medical illness; neurologic disorder (including seizures); pregnancy; meeting past or present criteria for any diagnosis on the K-SADS-PL(7); meeting the criteria for severe mood and behavioral dysregulation; meeting criterion of post-traumatic stress disorder (exposure to a traumatic event).

Special Instructions: Currently Not Provided
Keywords:
Mood Disorders
Bipolar Disorder
Neuroimaging
Psychophysiology
Frustration
Emotional Dysregulation
Lithium
Conduct Disorder
Children and Adolescents
Affective Neuroscience
Recruitment Keywords:
Behavioral Dysregulation
Mood Disorder
Behavior
Children
Adolescent
Healthy Volunteer
HV
Normal Control
Conditions:
Mood Disorder
Investigational Drug(s):
None
Investigational Device(s):
None

Contacts:
Patient Recruitment and Public Liaison Office
Building 61
10 Cloister Court
Bethesda, Maryland 20892-4754
Toll Free: 1-800-411-1222
TTY: 301-594-9774 (local),1-866-411-1010 (toll free)
Fax: 301-480-9793

Electronic Mail:prpl@mail.cc.nih.gov

Citations: Not Provided

Active Accrual, Protocols Recruiting New Patients

If you have:


Command Menu Bar

Search The Studies | Help | Questions |
Clinical Center Home | NIH Home


Clinical Center LogoWarren Grant Magnuson Clinical Center (CC)
National Institutes of Health (NIH)
Bethesda, Maryland 20892. Last update: 10/16/2004

Search The Studies Help Questions